Review
doi: 10.1056/NEJMct0807960.
Treatment of non-small-cell lung cancer with erlotinib or gefitinib
Affiliations
- PMID: 21388312
- DOI: 10.1056/NEJMct0807960
Item in Clipboard
Review
Treatment of non-small-cell lung cancer with erlotinib or gefitinib
N Engl J Med.
.
Abstract
A 64-year-old woman receives the diagnosis of metastatic non-small-cell lung cancer (NSCLC), which has progressed during treatment with carboplatin, paclitaxel, and bevacizumab. Erlotinib therapy is recommended.
Comment in
-
Erlotinib or gefitinib for non-small-cell lung cancer.N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918. N Engl J Med. 2011. PMID: 21675909 No abstract available.
-
Erlotinib or gefitinib for non-small-cell lung cancer.N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918. N Engl J Med. 2011. PMID: 21675910 No abstract available.
Similar articles
-
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).Oncologist. 2010;15(12):1344-51. doi: 10.1634/theoncologist.2010-0257. Epub 2010 Dec 10. Oncologist. 2010. PMID: 21148614 Free PMC article. Clinical Trial.
-
Histology matters: individualizing treatment in non-small cell lung cancer.Oncologist. 2010;15(1):3-5. doi: 10.1634/theoncologist.2009-0306. Epub 2010 Jan 19. Oncologist. 2010. PMID: 20086166 Free PMC article.
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285168 Clinical Trial.
-
Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.Clin Lung Cancer. 2004 Dec;6 Suppl 1:S24-9. doi: 10.3816/clc.2004.s.011. Clin Lung Cancer. 2004. PMID: 15638954 Review.
-
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Med Oncol. 2014 Aug;31(8):78. doi: 10.1007/s12032-014-0078-5. Epub 2014 Jun 24. Med Oncol. 2014. PMID: 24958518 Review.
Cited by
-
Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell.Medicine (Baltimore). 2020 Jul 2;99(27):e20944. doi: 10.1097/MD.0000000000020944. Medicine (Baltimore). 2020. PMID: 32629699 Free PMC article.
-
Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.Adv Exp Med Biol. 2013;734:91-107. doi: 10.1007/978-1-4614-1445-2_6. Adv Exp Med Biol. 2013. PMID: 23143977 Free PMC article.
-
PTPσ inhibitors promote hematopoietic stem cell regeneration.Nat Commun. 2019 Aug 14;10(1):3667. doi: 10.1038/s41467-019-11490-5. Nat Commun. 2019. PMID: 31413255 Free PMC article.
-
Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.Cancer Sci. 2019 Sep;110(9):2884-2893. doi: 10.1111/cas.14120. Epub 2019 Aug 1. Cancer Sci. 2019. PMID: 31265163 Free PMC article. Clinical Trial.
-
EGFR Activation Impairs Antiviral Activity of Interferon Signaling in Brain Microvascular Endothelial Cells During Japanese Encephalitis Virus Infection.Front Microbiol. 2022 Jun 30;13:894356. doi: 10.3389/fmicb.2022.894356. eCollection 2022. Front Microbiol. 2022. PMID: 35847084 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
